Akamis Bio
13
1
1
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Role: lead
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Role: lead
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Role: collaborator
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
Role: lead
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
Role: lead
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
Role: lead
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer
Role: collaborator
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
Role: lead
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Role: lead
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
Role: lead
Mechanism of Action Trial of ColoAd1
Role: lead
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
Role: lead
A Clinical Study With MT-102 in Subjects With Cancer Cachexia
Role: lead
All 13 trials loaded